Dec 21, 2022

Featuring perspectives from Dr Thomas Herzog, including the following topics:

• Impact of PARP inhibitors (PARPi) on the care of patients with ovarian cancer (0:00)
• Clarifying the recent withdrawal of PARPi for treatment of recurrent or refractory ovarian cancer (4:13)
• Sequential use of PARPi for patients with advanced ovarian cancer (16:56)
• Case: Woman in her late 60s with BRCA wild type ovarian cancer (20:06)
• Case: Woman in her early 50s with somatic BRCA-positive high-grade serous ovarian cancer (39:22)
• Case: Woman in her mid 60s with BRCA wild type and homologous recombination-deficient endometroid ovarian cancer (44:02)

CME information and select publications